• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

    41.67 -2.55 (-5.77%)
    Streaming Delayed Price Updated: 4:00 PM EST, Feb 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Collegium Pharmaceutical, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Why Collegium Pharmaceutical (COLL) Stock Is Trading Lower Today
    Shares of pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell 6.7% in the afternoon session after the company reported fourth-quarter earnings and revenue that fell short of analysts'... 
    Via StockStory
    News headline image
    Collegium (COLL) Q4 2025 Earnings Call Transcript ↗
    Collegium (COLL) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    Collegium Pharmaceutical Inc (NASDAQ:COLL) Reports Q4 Revenue Growth but Misses Earnings Estimates ↗
    Via Chartmill
    News headline image
    Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 CY2025 Earnings Results: Revenue In Line With Expectations
    Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 12.9% year on year to $205.4 million. The company’s full-year revenue... 
    Via StockStory
    COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) Presents a Classic Value Case with High Earnings and Low Valuation ↗
    Via Chartmill
    Collegium Pharmaceutical Inc (NASDAQ:COLL) Presents a Compelling Value Investment Case ↗
    Via Chartmill
    News headline image
    Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    News headline image
    Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect
    Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to expect. 
    Via StockStory
    Topics World Trade
    News headline image
    Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    News headline image
    Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    News headline image
    1 Profitable Stock on Our Watchlist and 2 That Underwhelm
    While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
    Via StockStory
    News headline image
    Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    News headline image
    Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 ↗
    An executive vice president at a top pharmaceutical company sold shares towards the end of 2025, while the company's shares reached record numbers that year. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    3 Small-Cap Stocks We’re Skeptical Of
    Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
    Via StockStory
    News headline image
    Collegium Provides 2026 Financial Guidance and Business Update
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    News headline image
    3 Russell 2000 Stocks Walking a Fine Line
    The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
    Via StockStory
    News headline image
    Collegium Announces the Closing of $980 Million Syndicated Credit Facility
    Five-Year Financing with Favorable Terms that Significantly Reduce Interest Rate 
    From Collegium Pharmaceutical, Inc.
    Via GlobeNewswire
    News headline image
    2 Reasons to Avoid COLL and 1 Stock to Buy Instead
    Collegium Pharmaceutical has been on fire lately. In the past six months alone, the company’s stock price has rocketed 68.7%, setting a new 52-week high of $49.89 per share. This was partly thanks to... 
    Via StockStory
    Topics Supply Chain
    News headline image
    3 Cash-Producing Stocks We Think Twice About
    While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
    Via StockStory
    News headline image
    Collegium Pharmaceutical Inc (NASDAQ:COLL) Shows Strong Earnings Momentum and Bullish Technical Setup ↗
    Collegium Pharmaceutical (COLL) shows strong earnings growth and a bullish technical setup, offering a potential breakout opportunity for momentum investors. 
    Via Chartmill
    News headline image
    3 Unpopular Stocks We Find Risky
    When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
    Via StockStory
    News headline image
    Collegium Pharmaceutical Inc (NASDAQ:COLL) Fits the Minervini Growth Momentum Strategy ↗
    Collegium Pharmaceutical (COLL) aligns with Mark Minervini's SEPA strategy, showing a strong technical uptrend and robust fundamental earnings and sales growth. 
    Via Chartmill
    News headline image
    Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)
    As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers. 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    1 Growth Stock Set to Flourishand 2 Facing Challenges
    Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
    Via StockStory
    News headline image
    1 Mooning Stock with Promising Prospects and 2 Facing Challenges
    Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. 
    Via StockStory
    News headline image
    1 Small-Cap Stock with Exciting Potential and 2 We Avoid
    Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
    Via StockStory
    News headline image
    Branded Pharmaceuticals Stocks Q3 Earnings: Eli Lilly (NYSE:LLY) Best of the Bunch
    The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Eli Lilly (NYSE:LLY) and the... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Collegium Pharmaceutical Inc (NASDAQ:COLL) Shows High Growth Momentum with Strong Technicals ↗
    Discover how Collegium Pharmaceutical (COLL) combines a strong technical uptrend with powerful earnings growth, marking it as a high-potential stock. 
    Via Chartmill
    News headline image
    5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q3 Earnings Call
    Collegium Pharmaceutical’s third quarter was marked by robust demand for its ADHD medication Jornay PM and continued resilience in its pain management portfolio. Management pointed to a successful... 
    Via StockStory
    Topics Earnings
    News headline image
    1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off
    Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
    Via StockStory
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.